Pioglitazone Group (n = 36) | Empagliflozin Group (n = 37) | ||||||
---|---|---|---|---|---|---|---|
Variable | Baseline | After 24 weeks | P value | Baseline | After 24 weeks | P value | P value* |
Systolic (mmHg) | 117.5 ± 14.5 | 114.8 ± 11.7 | 0.23 | 116.8 ± 11.8 | 113.5 ± 11.3 | 0.01 | 0.80 |
Diastolic (mmHg) | 75.2 ± 11.3 | 71.2 ± 8.2 | 0.03 | 77.5 ± 9.4 | 72.5 ± 9.1 | < 0.01 | 0.62 |
EF (%) | 58.7 ± 8.1 | 58.7 ± 4.5 | 0.99 | 57.9 ± 6.9 | 59.1 ± 6.5 | 0.38 | 0.55 |
GLS (%) | -19.07 ± 2.40 | -20.64 ± 1.72 | < 0.01 | -19.65 ± 2.15 | -20.72 ± 1.56 | < 0.01 | 0.31 |
E (cm/s) | 0.66 ± 0.11 | 0.71 ± 0.13 | 0.01 | 0.64 ± 0.12 | 0.66 ± 0.11 | 0.50 | 0.14 |
A (cm/s) | 0.68 ± 0.13 | 0.71 ± 0.13 | 0.04 | 0.67 ± 0.16 | 0.69 ± 0.16 | 0.38 | 0.48 |
E/A | 1.00 ± 0.26 | 1.04 ± 0.29 | 0.31 | 1.00 + 0.29 | 0.99 + 0.27 | 0.87 | 0.51 |
e´ (cm/s) | 6.8 ± 1.5 | 7.5 ± 1.6 | 0.01 | 6.5 ± 1.5 | 7.3 ± 1.7 | < 0.01 | 0.82 |
E/ e´ | 9.7 ± 2.0 | 9.4 ± 1.6 | 0.39 | 9.9 ± 2.4 | 9.0 ± 1.8 | 0.04 | 0.31 |
DT (ms) | 221.9 ± 39.5 | 205.9 ± 52.1 | 0.12 | 201.0 ± 33.4 | 213.0 ± 48.8 | 0.13 | 0.03 |
IVRT (ms) | 108.1 ± 13.8 | 100.0 ± 15.7 | 0.02 | 107.1 ± 15.9 | 106.9 ± 13.7 | 0.95 | 0.07 |
LV end-diastolic diameter (cm) | 4.4 ± 0.4 | 4.4 ± 0.4 | 0.79 | 4.6 ± 0.4 | 4.5 ± 0.4 | 0.20 | 0.42 |
LV end-systolic diameter (cm) | 2.9 ± 0.4 | 2.8 ± 0.3 | 0.17 | 3.1 ± 0.4 | 2.9 ± 0.4 | 0.10 | 0.84 |
LAVi (ml/m2) | 23.0 ± 4.1 | 24.2 ± 5.0 | 0.28 | 21.7 ± 6.2 | 21.1 ± 1.1 | 0.40 | 0.16 |
LA area (cm2) | 15.7 ± 2.3 | 16.3 ± 2.1 | 0.10 | 15.4 ± 2.5 | 15.6 ± 2.2 | 0.59 | 0.43 |
PAP (mmHg) | 24.9 ± 3.3 | 25.1 ± 3.1 | 0.86 | 24.9 ± 3.3 | 25.2 ± 3.3 | 0.72 | 0.92 |